Clinical trials with glycoprotein IIB/IIIA antagonists no benefit without bleeding?

Drugs of Today

Volumn 37, Issue 8, 2001, Pages 509-531

  Doggrell, S A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; ORBOFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; XEMILOFIBAN;

ACUTE HEART INFARCTION; ATHERECTOMY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY STENT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; ISCHEMIA; META ANALYSIS; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

EID: 0035154044     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.8.844169     Document Type: Review

References (79)

1. Thrombolysis in Myocardial Infarction (TIMI) Trial phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
3. Antiplatelet therapy: Glycoprotein IIb/IIIa receptor antagonists
4. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
5. Early and late outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: The EPIC Trial results
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
7. Bleeding complications with chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
8. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial
9. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists
10. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation of c7E3 for the Prevention of Ischemic Complications
11. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
12. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications
13. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications
14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
15. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-Term Outcome with abciximab GP IIb/IIIa blockade
16. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications
17. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial
18. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
19. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) study investigators
20. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Reo-Pro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
21. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty
22. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
23. Efficacy of abciximab readministration in coronary intervention
24. Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access
25. Multicenter, randomized, double blind trial of platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention
26. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
27. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
28. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes of Restenosis
29. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes of Restenosis
30. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
31. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
32. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy
33. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
34. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
35. Unexpected mortality reduction with abciximab for in-stent restenosis
36. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts
37. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patient after coronary stent deployment
38. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
39. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
40. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
41. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study
42. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E GP IIb/IIIa Receptor Blockade
43. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy
44. Enhanced efficacy of eptifibafide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting
45. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy
46. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban study
47. The Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
48. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study. The PARAGON B International Steering Committee
49. Effects of Integrilin a platelet IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial
50. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrifin Therapy
51. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial
52. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial experience
53. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using Integrilin therapy (PURSUIT) trial
54. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
55. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
56. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
57. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes
58. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
59. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management
60. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
61. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results for the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)
62. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients present with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study
63. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes with ST-elevation; a phase II study
64. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events post-acute Coronary Syndromes
65. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
66. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
67. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial
68. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
69. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study
70. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators
71. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
72. Design of the Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial
73. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials
74. Effect of smoking status and abciximab use on outcome after percutaneous revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT
75. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
76. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
77. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
78. Incidence of intracranial hemorrhage complication treatment with glycopotein IIb/IIIa inhibitors: A pooled analysis of major clinical trials
79. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention